Investment company news brought to you by Citywire Financial Publishers Limited and Quoted Data by Marten & Co.

Pantheon Infrastructure shifts to capital management as dividend cover raises concerns

The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.

Pantheon shifts to capital management as dividend cover raises concerns

The infrastructure trust has spent almost all of its cash resources and will be cautious about future investment as it weighs up its other commitments.

Boss of one-time Woodford-favourite biotech leaves amid strategic review

Arix Bioscience chief executive Robert Lyne departs midway through a strategic review with the shares trading at a 38% discount.

Exiting Symphony finally plays tune that shareholders want

Symphony International, a badly-performing Asia private equity fund, announces ‘orderly realisation’ of its assets after failing to revive its heavily discounted share price.

Aurora offers fee-free rally but Buffett disciple not yet ‘raining gold’

Garry Channon's unusual Netflix-holding UK value fund stages first half turnaround despite its new position in Hotel Chocolat suffering a share price meltdown.

Floating rate loans boost BioPharma Credit earnings

The dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, however, problems with LumiraDx continue to be a concern for analysts.

BioPharama's solid results overshadowed by distressed LumiraDX loan

Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.

BioPharma's solid results overshadowed by distressed LumiraDX loan

Dollar-denominated trust saw a 21% increase in earnings per share as biotech companies turned to private debt, but problems with LumiraDx continue to concern analysts.

Abrdn’s closure of investment trust saving plans angers investors

Abrdn is closing its historic investment trust savings plans and annoying investors with the transfer of their holdings to Interactive Investor, the online stockbroker it owns.

Life Science Reit: Recovery is coming but we've got to be creative

Life Science Reit is looking at creative ways of funding for the future as manager Simon Farnsworth remains optimistic following its launch into a tough market.

Manager of ThomasLloyd Energy beaten again as investors back board

Nearly two-thirds of the renewables fund’s independent shareholders vote to retain its board, resisting removal efforts by dismissed fund manager ThomasLloyd Global.

Schroders Capital sells £24.5m of investments to fund share buybacks

The trust formerly known as Woodford Patient Capital sells 22% of its publicly quoted holdings to pay for share buybacks to help rerate its depressed stock.